Lilly To Give High-Risk Alzheimer’s Drug “Every Chance,” says Lechleiter At JP Morgan
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly is relying heavily on biomarkers to help its Alzheimer’s disease-modifying drug solanezumab progress, executives tell a crowd of analysts at JP Morgan,